Organization
MetroHealth Cancer Center
1 abstract
Abstract
Two phase 2A clinical trials to evaluate the safety and efficacy of IMSA101 in combination with radiotherapy and checkpoint inhibitors in oligometastatic and oligoprogressive solid tumor malignancies.Org: MetroHealth Cancer Center, University of Wisconsin Madison, Cleveland VA,